Tissue factor pathway inhibitor - cofactor-dependent regulation of the initiation of coagulation.
Journal
Current opinion in hematology
ISSN: 1531-7048
Titre abrégé: Curr Opin Hematol
Pays: United States
ID NLM: 9430802
Informations de publication
Date de publication:
27 Aug 2024
27 Aug 2024
Historique:
medline:
11
9
2024
pubmed:
11
9
2024
entrez:
11
9
2024
Statut:
aheadofprint
Résumé
In humans, tissue factor pathway inhibitor (TFPI) exists in two alternatively spliced isoforms, TFPIα and TFPIβ. TFPIα consists of three Kunitz domains (K1, K2 and K3) and a highly basic C-terminal tail. K1 inhibits the tissue factor-activated factor VII complex, K2 specifically inhibits activated factor X, K3 is essential for interaction with its cofactor, protein S, and the basic C-terminus is binds factor V-short (FV-short) with high affinity. TFPIβ consists of K1 and K2 that is glycosylphosphatidylinositol anchored directly to cell surfaces. This review explores the structure/function of TFPI and its cofactors (protein S and FV-short), and the relative contributions that different TFPI isoforms may play in haemostatic control. Recent data have underscored the importance of TFPIα function and its reliance on its cofactors, protein S and FV-short, in influencing haemostatic control as well as bleeding and thrombotic risk. TFPIα is likely the most important pool of TFPI in modifying the risk of thrombosis and bleeding. TFPIα forms a trimolecular complex with FV-short and protein S in plasma. FV-short expression levels control the circulating levels of TFPIα, whereas protein S exerts essential cofactor mediated augmentation of it anticoagulant function.
Identifiants
pubmed: 39259668
doi: 10.1097/MOH.0000000000000838
pii: 00062752-990000000-00087
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Références
Crawley JT, Zanardelli S, Chion CK, et al. The central role of thrombin in hemostasis. J Thromb Haemost 2007; 5: (Suppl 1): 95–101.
Rezaie AR, Giri H. Anticoagulant and signaling functions of antithrombin. J Thromb Haemost 2020; 18:3142–3153.
Griffin JH, Fernandez JA, Gale AJ, et al. Activated protein C. J Thromb Haemost 2007; 5: (Suppl 1): 73–80.
Crawley JT, Lane DA. The haemostatic role of tissue factor pathway inhibitor. Arterioscler Thromb Vasc Biol 2008; 28:233–242.
Mast AE. Tissue factor pathway inhibitor: multiple anticoagulant activities for a single protein. Arterioscler Thromb Vasc Biol 2016; 36:9–14.
Hackeng TM, Sere KM, Tans G, et al. Protein S stimulates inhibition of the tissue factor pathway by tissue factor pathway inhibitor. Proc Natl Acad Sci USA 2006; 103:3106–3111.
Ahnstrom J, Andersson HM, Hockey V, et al. Identification of functionally important residues in TFPI Kunitz domain 3 required for the enhancement of its activity by protein S. Blood 2012; 120:5059–5062.
Ndonwi M, Tuley EA, Broze GJ Jr. The Kunitz-3 domain of TFPI-alpha is required for protein S-dependent enhancement of factor Xa inhibition. Blood 2010; 116:1344–1351.
Vincent LM, Tran S, Livaja R, et al. Coagulation factor V(A2440G) causes east Texas bleeding disorder via TFPIalpha. J Clin Invest 2013; 123:3777–3787.
Zhang J, Piro O, Lu L, et al. Glycosyl phosphatidylinositol anchorage of tissue factor pathway inhibitor. Circulation 2003; 108:623–627.
Maroney SA, Ellery PE, Wood JP, et al. Comparison of the inhibitory activities of human tissue factor pathway inhibitor (TFPI)alpha and TFPIbeta. J Thromb Haemost 2013; 11:911–918.
Piro O, Broze GJ Jr. Comparison of cell-surface TFPIalpha and beta. J Thromb Haemost 2005; 3:2677–2683.
Reglinska-Matveyev N, Andersson HM, Rezende SM, et al. TFPI cofactor function of protein S: essential role of the protein S SHBG-like domain. Blood 2014; 123:3979–3987.
Teraz-Orosz A, Gierula M, Petri A, et al. Laminin G1 residues of protein S mediate its TFPI cofactor function and are competitively regulated by C4BP. Blood Adv 2022; 6:704–715.
Somajo S, Ahnstrom J, Fernandez-Recio J, et al. Amino acid residues in the laminin G domains of protein S involved in tissue factor pathway inhibitor interaction. Thromb Haemost 2015; 113:976–987.
Wood JP, Bunce MW, Maroney SA, et al. Tissue factor pathway inhibitor-alpha inhibits prothrombinase during the initiation of blood coagulation. Proc Natl Acad Sci USA 2013; 110:17838–17843.
Dahlback B, Tran S. The preAR2 region (1458-1492) in factor V-Short is crucial for the synergistic TFPIalpha-cofactor activity with protein S and the assembly of a trimolecular factor Xa-inhibitory complex comprising FV-Short, protein S, and TFPIalpha. J Thromb Haemost 2022; 20:58–68.
Dahlback B, Tran S. A hydrophobic patch (PLVIVG; 1481-1486) in the B-domain of factor V-short is crucial for its synergistic TFPIalpha-cofactor activity with protein S and for the formation of the FXa-inhibitory complex comprising FV-short, TFPIalpha, and protein S. J Thromb Haemost 2022; 20:1146–1157.
Gierula M, Noakes VM, Salles C II, et al. The TFPIalpha C-terminal tail is essential for TFPIalpha-FV-short-protein S complex formation and synergistic enhancement of TFPIalpha. J Thromb Haemost 2023; 21:3568–3580.
Santamaria S, Reglinska-Matveyev N, Gierula M, et al. Factor V has an anticoagulant cofactor activity that targets the early phase of coagulation. J Biol Chem 2017; 292:9335–9344.
Dahlback B, Guo LJ, Livaja-Koshiar R, et al. Factor V-short and protein S as synergistic tissue factor pathway inhibitor (TFPIalpha) cofactors. Res Pract Thromb Haemost 2018; 2:114–124.
Girard TJ, Grunz K, Lasky NM, et al. Re-evaluation of mouse tissue factor pathway inhibitor and comparison of mouse and human tissue factor pathway inhibitor physiology. J Thromb Haemost 2018; 16:2246–2257.
Petri A, Sasikumar P, Folgado PB, et al. TFPIalpha anticoagulant function is highly dependent on protein S in vivo. Sci Adv 2024; 10:eadk5836.
Wood JP, Ellery PE, Maroney SA, et al. Protein S is a cofactor for platelet and endothelial tissue factor pathway inhibitor-alpha but not for cell surface-associated tissue factor pathway inhibitor. Arterioscler Thromb Vasc Biol 2014; 34:169–176.
Ndonwi M, Broze G Jr. Protein S enhances the tissue factor pathway inhibitor inhibition of factor Xa but not its inhibition of factor VIIa-tissue factor. J Thromb Haemost 2008; 6:1044–1046.
Cunha ML, Bakhtiari K, Peter J, et al. A novel mutation in the F5 gene (factor V Amsterdam) associated with bleeding independent of factor V procoagulant function. Blood 2015; 125:1822–1825.
Zimowski KL, Petrillo T, Ho MD, et al. F5-Atlanta: A novel mutation in F5 associated with enhanced East Texas splicing and FV-short production. J Thromb Haemost 2021; 19:1653–1665.
Duckers C, Simioni P, Spiezia L, et al. Low plasma levels of tissue factor pathway inhibitor in patients with congenital factor V deficiency. Blood 2008; 112:3615–3623.
Rietveld IM, Bos MHA, Lijfering WM, et al. Factor V levels and risk of venous thrombosis: the MEGA case-control study. Res Pract Thromb Haemost 2018; 2:320–326.
Maroney SA, Haberichter SL, Friese P, et al. Active tissue factor pathway inhibitor is expressed on the surface of coated platelets. Blood 2007; 109:1931–1937.
Maroney SA, Siebert AE, Martinez ND, et al. Platelet tissue factor pathway inhibitor-alpha dampens cardiac thrombosis and associated fibrosis in mice. J Thromb Haemost 2023; 21:639–651.
Tardy-Poncet B, Montmartin A, Chambost H, et al. Relationship between plasma tissue factor pathway inhibitor (TFPI) levels, thrombin generation and clinical risk of bleeding in patients with severe haemophilia A or B. Haemophilia 2024; 30:693–701.